Medmix Ltd
SIX:MEDX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.64
19
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medmix Ltd
Medmix Ltd
Cost of Revenue
Medmix Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medmix Ltd
SIX:MEDX
|
Cost of Revenue
-CHf328.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Metall Zug AG
SIX:METN
|
Cost of Revenue
-CHf314.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-8%
|
|
|
Sonova Holding AG
SIX:SOON
|
Cost of Revenue
-CHf1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Medacta Group SA
SIX:MOVE
|
Cost of Revenue
-€162.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Straumann Holding AG
SIX:STMN
|
Cost of Revenue
-CHf623.4m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Medmix Ltd
Glance View
medmix AG designs, develops and produces delivery devices for the mixing, application and injection of liquids for the healthcare, consumer and industrial end-markets. The company is headquartered in Zug, Zug and currently employs 2,101 full-time employees. The firm operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
See Also
What is Medmix Ltd's Cost of Revenue?
Cost of Revenue
-328.9m
CHF
Based on the financial report for Dec 31, 2023, Medmix Ltd's Cost of Revenue amounts to -328.9m CHF.
What is Medmix Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-3%
Over the last year, the Cost of Revenue growth was -9%. The average annual Cost of Revenue growth rates for Medmix Ltd have been -13% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
